BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Gao H, Liu W, Qin Y, Ye Z, Lou X, Wang F, Zhang Y, Chen X, Chen J, Yu X, Zhuo Q, Xu X, Ji S. A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival. Front Endocrinol 2022;13:941210. [DOI: 10.3389/fendo.2022.941210] [Reference Citation Analysis]
2 Caban M, Małecka-wojciesko E. Pancreatic Incidentaloma. JCM 2022;11:4648. [DOI: 10.3390/jcm11164648] [Reference Citation Analysis]
3 Hackeng WM, Assi HA, Westerbeke FH, Brosens LA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.007] [Reference Citation Analysis]
4 Quan L, Liu Y, Cui W, Wang X, Zhang W, Wang Z, Guo C, Lu C, Hu F, Chen X. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms. Lipids Health Dis 2022;21:58. [PMID: 35842659 DOI: 10.1186/s12944-022-01669-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang Z, Liang J, Leng K, Shi G. Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis. Front Oncol 2022;12:903560. [DOI: 10.3389/fonc.2022.903560] [Reference Citation Analysis]
6 Cigrovski Berkovic M, Ulamec M, Marinovic S, Balen I, Mrzljak A. Malignant insulinoma: Can we predict the long-term outcomes? World J Clin Cases 2022; 10(16): 5124-5132 [DOI: 10.12998/wjcc.v10.i16.5124] [Reference Citation Analysis]
7 Xu J, Yang J, Feng Y, Zhang J, Zhang Y, Chang S, Jin J, Du X. MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas. Front Oncol 2022;12:856306. [DOI: 10.3389/fonc.2022.856306] [Reference Citation Analysis]
8 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yang Z, Shi G. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.016] [Reference Citation Analysis]
10 Stankiewicz R, Grąt M. Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(4): 276-285 [DOI: 10.4240/wjgs.v14.i4.276] [Reference Citation Analysis]
11 Ishida H, Lam AK. Pancreatic Neuroendocrine Neoplasms: Updates on Genomic Changes in Inherited Tumour Syndromes and Sporadic Tumours Based on WHO Classification. Crit Rev Oncol Hematol 2022;:103648. [PMID: 35248713 DOI: 10.1016/j.critrevonc.2022.103648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Shyr BS, Shyr BU, Chen SC, Shyr YM, Wang SE. Impact of tumor grade on pancreatic neuroendocrine tumors. Asian J Surg 2022:S1015-9584(22)00149-X. [PMID: 35246343 DOI: 10.1016/j.asjsur.2022.01.094] [Reference Citation Analysis]
13 Chauhan A, Prieur A, Kolesar J, Arnold S, Payen L, Mahi Y, Vire B, Sands M, Evers BM, Joubert D, Anthony L. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors. Cancers (Basel) 2022;14:863. [PMID: 35205614 DOI: 10.3390/cancers14040863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci 2022;23:1447. [PMID: 35163374 DOI: 10.3390/ijms23031447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mason D, Leimbach R, Kitz R, Vietor R, Vietor N. Calcitonin‐secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine‐needle aspirate calcitonin washout: A case report and review of the literature. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5296] [Reference Citation Analysis]
16 Havasi A, Sur D, Cainap SS, Lungulescu CV, Gavrilas LI, Cainap C, Vlad C, Balacescu O. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers. Int J Mol Sci 2022;23:1109. [PMID: 35163032 DOI: 10.3390/ijms23031109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Opalińska M, Sowa-Staszczak A, Olearska H, Ulatowska-Bialas M, Gilis-Januszewska A, Hubalewska-Dydejczyk A. Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma. Front Endocrinol (Lausanne) 2021;12:770266. [PMID: 34917031 DOI: 10.3389/fendo.2021.770266] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Frey S, Mirallié E, Le Bras M, Regenet N. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers (Basel) 2021;13:5954. [PMID: 34885063 DOI: 10.3390/cancers13235954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Vivanet G, Gervaso L, Laffi A, Rubino M, Spada F, Fazio N. Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. Expert Opin Drug Saf 2021;:1-8. [PMID: 34724869 DOI: 10.1080/14740338.2022.2000964] [Reference Citation Analysis]
21 Hu T, Wang W, He C. Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis. J Oncol 2021;2021:1565089. [PMID: 34754307 DOI: 10.1155/2021/1565089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Wang H, Ding D, Qin T, Zhang H, Liu J, Zhao J, Wu CH, Javed A, Wolfgang C, Guo S, Chen Q, Zhao W, Shi W, Zhu F, Guo X, Li X, Peng F, He R, Xu S, Jin J, Wu Y, Nuer A, Edil B, Tien YW, Jin G, Zheng L, He J, Liu J, Liu Y, Wang M, Qin R; Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare. Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. HPB (Oxford) 2021:S1365-182X(21)01671-3. [PMID: 34836754 DOI: 10.1016/j.hpb.2021.10.017] [Reference Citation Analysis]
23 Curigliano G, Martin M, Jhaveri K, Beck JT, Tortora G, Fazio N, Maur M, Hubner RA, Lahner H, Donnet V, Ajipa O, Li Z, Blumenstein L, Andre F. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. Eur J Cancer 2021;151:49-62. [PMID: 33964572 DOI: 10.1016/j.ejca.2021.03.042] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
25 Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology 2021;21:215-23. [PMID: 33358592 DOI: 10.1016/j.pan.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]